Related Experiment Videos
2019 update of the drug resistance mutations in HIV-1
Annemarie M Wensing1, Vincent Calvez2, Francesca Ceccherini-Silberstein3
1University Medical Center Utrecht, The Netherlands and University of the Witwatersrand, Johannesburg, South Africa.
Insights
The updated IAS-USA list details key drug resistance mutations for antiretroviral drugs. This resource aids clinicians in making informed treatment decisions for HIV patients.
Area of Science:
- Antiviral drug resistance
- HIV/AIDS therapeutics
- Molecular epidemiology
Background:
- Antiretroviral therapy (ART) is crucial for managing HIV.
- Emergence of drug resistance mutations (DRMs) complicates ART efficacy.
- Regular updates are needed to reflect current scientific understanding.
Purpose of the Study:
- To present the 2019 edition of the IAS-USA list of DRMs.
- To provide an updated reference for clinicians treating HIV.
- To highlight mutations associated with specific antiretroviral drugs.
Main Methods:
- Compilation of DRMs based on established evidence criteria.
- Focus on mutations linked to specific antiretroviral drug classes.
- Inclusion of updated information since the January 2017 list.
Main Results:
- The 2019 list incorporates newly identified DRMs.
- Specific mutations are linked to resistance against various antiretroviral agents.
- The list serves as a practical tool for clinical application.
Conclusions:
- The updated IAS-USA list is essential for guiding ART selection.
- Accurate identification of DRMs improves patient outcomes.
- This resource supports evidence-based clinical decision-making in HIV management.
Abstract:
The 2019 edition of the IAS-USA drug resistance mutations list updates the Figure last published in January 2017. The mutations listed are those that have been identified by specific criteria for evidence and drugs described. The Figure is designed to assist practitioners in identifying key mutations associated with resistance to antiretroviral drugs, and therefore, in making clinical decisions regarding antiretroviral therapy.